The Rewards Of Intellectual Bigamy

Carl Djerassi's two track career in academia has brought him both fame and wealth STANFORD, CALIF.--If there's any doubt that a scientist can honorably serve two masters, Carl Djerassi stands as living proof. For the last 36 years, the chemist has been a self-described "intellectual bigamist"--partaking of the freedom of academia while churning out discovery after lucrative discovery for industry. And while other scientists, particularly in the fields of biotechnology and computer science, h

| 9 min read

Register for free to listen to this article
Listen with Speechify
0:00
9:00
Share

Carl Djerassi's two track career in academia has brought him both fame and wealth

STANFORD, CALIF.--If there's any doubt that a scientist can honorably serve two masters, Carl Djerassi stands as living proof. For the last 36 years, the chemist has been a self-described "intellectual bigamist"--partaking of the freedom of academia while churning out discovery after lucrative discovery for industry. And while other scientists, particularly in the fields of biotechnology and computer science, have walked the delicate line between academic and commercial science, few can match Djerassi's juggling act for success and longevity.

A professor of chemistry at Stanford University since 1960, Djerassi has directed or founded four companies, synthesized the first oral contraceptive, pioneered the synthesis of cortisone from plants, developed new applications for such standard organic chemistry tools as the mass spectrometer, published 1,150 papers and eight books--and become a millionaire. Not bad for a man who arrived ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

  • Virginia Morell

    This person does not yet have a bio.

Published In

Share
May digest 2025 cover
May 2025, Issue 1

Study Confirms Safety of Genetically Modified T Cells

A long-term study of nearly 800 patients demonstrated a strong safety profile for T cells engineered with viral vectors.

View this Issue
iStock

TaqMan Probe & Assays: Unveil What's Possible Together

Thermo Fisher Logo
Meet Aunty and Tackle Protein Stability Questions in Research and Development

Meet Aunty and Tackle Protein Stability Questions in Research and Development

Unchained Labs
Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Bio-Rad
How technology makes PCR instruments easier to use.

Making Real-Time PCR More Straightforward

Thermo Fisher Logo

Products

The Scientist Placeholder Image

Biotium Launches New Phalloidin Conjugates with Extended F-actin Staining Stability for Greater Imaging Flexibility

Leica Microsystems Logo

Latest AI software simplifies image analysis and speeds up insights for scientists

BioSkryb Genomics Logo

BioSkryb Genomics and Tecan introduce a single-cell multiomics workflow for sequencing-ready libraries in under ten hours

iStock

Agilent BioTek Cytation C10 Confocal Imaging Reader

agilent technologies logo